Im­munome stops Covid-19 work; Hookipa drops CMV vac­cine

Im­munome is look­ing for a part­ner for its Covid-19 an­ti­body cock­tail known as IMM-BCP-01, ac­cord­ing to its an­nu­al re­port re­leased Thurs­day morn­ing. Un­til then, it will stop fur­ther de­vel­op­ment of the can­di­date.

The Ex­ton, PA-based biotech had test­ed the an­ti­body cock­tail in a Phase Ib tri­al with an es­ti­mat­ed en­roll­ment of 36 peo­ple who have mild to mod­er­ate Covid-19, ac­cord­ing to a fed­er­al clin­i­cal tri­als data­base. The tri­al was run in col­lab­o­ra­tion with the US DoD and was meant to look at the safe­ty of the drug. Im­munome said there were no sig­nif­i­cant treat­ment-re­lat­ed ad­verse events.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA